Ascendiant raised the firm’s price target on Lucid Diagnostics (LUCD) to $7.50 from $7 and keeps a Buy rating on the shares following the Q4 report. Lucid’s devices still have long commercialization and growth challenges ahead, but the “billion dollars market potential presents high rewards for the risks,” the analyst tells investors in a research note. The firm says the company’s expected high growth in 2025 should drive the stock “much higher.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics Closes $16.1 Million Public Offering
- Lucid Diagnostics: Strong Buy Rating Backed by Growth Potential and Competitive Edge in EsoGuard Testing
- Lucid Diagnostics Announces Public Stock Offering
- Lucid Diagnostics 12.5M share Spot Secondary priced at $1.20
- Closing Bell Movers: Futures sustaining gains after massive rebound
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue